Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) regularly issues news and updates about its application of artificial intelligence and machine learning to drug discovery and development. Company announcements highlight how its proprietary platforms bfLEAP® and bfPREP™ are used to analyze complex biomedical and clinical datasets and to support precision medicine strategies.
Investors and industry observers following BFRG news can expect coverage of collaborations with biopharmaceutical partners, such as work with Eleison Pharmaceuticals on oncology clinical trial data, and commercial relationships with organizations like Sygnature Discovery. Updates often describe how BullFrog AI’s technology is deployed to prepare and standardize legacy clinical records, identify biologically meaningful patient subgroups, and inform trial optimization and patient stratification efforts.
News items also discuss scientific validation milestones, including acceptance of abstracts for presentation at major oncology conferences such as the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. These communications provide detail on how BullFrog AI’s causal AI and human-in-the-loop workflows are applied to real-world datasets in areas like pancreatic cancer and other difficult-to-treat conditions.
In addition, BullFrog AI issues shareholder letters, webinar invitations, and whitepaper announcements that describe its enterprise-grade platform architecture, data preparation capabilities, and AI agent workflows. Readers of this news feed can use it to track the company’s commercial progress, scientific collaborations, technology enhancements, and capital markets developments as disclosed through press releases and related communications.
BullFrog AI Holdings (NASDAQ: BFRG) has entered into a collaboration agreement with Eleison Pharmaceuticals to optimize their Phase 3 clinical trial. The partnership will utilize BullFrog's Data Networks™ AI solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison's ongoing Phase 3 trial of glufosfamide for pancreatic cancer.
The AI platform will focus on:
- Evaluating trial trajectory regarding safety signals
- Extracting predictive biomarkers for efficacy and safety
- Supporting future trial design
- Providing data-driven insights for Eleison's planned clinical trials
Glufosfamide, a third-generation alkylating agent, is being evaluated for second-line treatment of pancreatic cancer, which affects over 67,000 Americans and 510,000 people worldwide annually, with five-year survival rates below 5%. Eleison expects to complete the Phase 3 trial in 2027.
BullFrog AI (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using artificial intelligence (AI) and machine learning, announced its participation in the TechBio track at Biotech Showcase and RESI JPM during the JP Morgan Healthcare Conference in San Francisco from January 13–16, 2025.
At these events, BullFrog AI will present its proprietary BullFrog Data Networks®, powered by the bfLEAP™ platform. This tool analyzes high-dimension, multi-modal data in specific disease indications, offering a visual representation of previously unknown relationships and pathways. The platform integrates various data sources, including public datasets like the Human Cell Atlas (HCA) and The Cancer Genome Atlas (TCGA), as well as proprietary data.
The BullFrog Data Networks® address the challenge of turning complex datasets into actionable insights, aiding in target identification, understanding mechanisms of action, optimizing clinical trials, and drug repurposing. The platform aims to reduce timelines and improve outcomes in drug development by providing intuitive visual insights and streamlining development processes.
BullFrog AI Holdings (NASDAQ: BFRG) released a stockholder letter highlighting key achievements in 2024. The company enhanced its bfLEAP™ platform by integrating new AI technologies licensed from Johns Hopkins University. Through collaboration with the Lieber Institute for Brain Development, they identified novel drug targets for neuropsychiatric disorders. Their research on BF-114 showed promise in treating obesity and liver diseases, while BF-223 secured additional patent protection for oncology applications.
The company strengthened its leadership by adding Dr. Thomas W. Chittenden as CSO and Dr. John Baldoni to the Scientific Advisory Board. BullFrog AI raised $8.83 million through two equity offerings in 2024, maintaining a strong cash position for future growth initiatives.
BullFrog AI Holdings (NASDAQ: BFRG) has appointed Josh Blacher as its new Chief Financial Officer, following the passing of former CFO Dane Saglio. Blacher brings over two decades of experience in strategic finance and corporate development for life science and biotech companies. His background includes roles as CFO at Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics, and senior positions at Teva Pharmaceuticals.
Blacher, who holds a BA in Economics from Yeshiva University and an MBA from Columbia Business School, will focus on strengthening the company's balance sheet, financial operations, and supporting strategic initiatives. His expertise includes SEC reporting, investor relations, and experience with both private and public companies.
BullFrog AI (NASDAQ: BFRG; BFRGW) announced that its VP of Artificial Intelligence, Dr. Enrique García-Rivera, will present at Google's inaugural Cancer AI Symposium on October 30, 2024, in Boston. The presentation will showcase BullFrog AI's use of AI in drug discovery and development, focusing on their proprietary bfLEAP™ platform. This platform integrates multimodal biological data to accelerate drug development, particularly in cancer research.
Dr. García-Rivera will highlight the company's collaboration with the Lieber Institute for Brain Development, demonstrating bfLEAP™'s versatility across various therapeutic areas. He will also introduce BullFrog AI's novel 'AlgoLLM' system for gene prioritization, which uses large language models to streamline the discovery of actionable insights in neuropsychiatric disorders and other diseases.
WallachBeth Capital announced the closing of BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) registered direct offering and concurrent private placement. The offering included:
- 1,565,000 shares of common stock (or equivalents)
- Common warrants to purchase up to 1,565,000 shares
- Combined purchase price of $2.00
- Gross proceeds of approximately $3.13 million
The warrants have an exercise price of $2.00 per share, are exercisable after six months, and expire five years from the initial exercise date. WallachBeth Capital, acted as sole placement agent for the offering.
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) has closed a previously announced definitive agreement for a registered direct offering and concurrent private placement. The company sold an aggregate of 1,565,000 shares of common stock (or equivalents) and warrants to purchase up to 1,565,000 shares at a combined price of $2.00. The gross proceeds from the offering are expected to be approximately $3.13 million.
The warrants have an exercise price of $2.00 per share, are initially exercisable six months from issuance, and will expire five years from the initial exercise date. WallachBeth Capital, acted as the sole placement agent for the offering. The shares and pre-funded warrants were issued under an effective shelf registration statement, while the common warrants were offered through a private placement.
WallachBeth Capital announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has entered into a definitive agreement for a registered direct offering and concurrent private placement. The offering includes:
- 1,565,000 shares of common stock (or equivalents)
- Common warrants to purchase up to 1,565,000 shares
- Combined purchase price of $2.00
- Warrant exercise price of $2.00 per share
The gross proceeds are expected to be approximately $3.13 million. The closing is anticipated around October 21, 2024. WallachBeth Capital, is acting as the sole placement agent for this offering.
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) has announced a registered direct offering and concurrent private placement for aggregate gross proceeds of $3.13 million. The offering includes:
- 1,565,000 shares of common stock (or equivalents)
- Common warrants to purchase up to 1,565,000 shares
- Combined purchase price of $2.00
- Warrant exercise price of $2.00 per share
The warrants will be initially exercisable six months from issuance and expire five years from the initial exercise date. The offering is expected to close around October 21, 2024. WallachBeth Capital, is acting as the sole placement agent for the offering.
BullFrog AI (NASDAQ: BFRG; BFRGW) has appointed Dr. John Baldoni to its Scientific Advisory Board. Dr. Baldoni brings over 40 years of pharmaceutical industry experience, including 29 years in R&D at GSK where he served as Senior Vice President of Platform and Technology Sciences. He is the co-founder of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium and former Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare.
Vin Singh, CEO of BullFrog AI, stated that Dr. Baldoni's experience in pharmaceutical R&D and leadership in technology-driven drug discovery will provide valuable insights for the commercialization of their bfLEAP™ platform. Dr. Baldoni expressed excitement about collaborating with BullFrog AI, recognizing the potential of the bfLEAP™ platform to transform complex biological data analysis in drug discovery and development.
FAQ
What is the current stock price of BULLFROG AI HLDGS (BFRG)?
What is the market cap of BULLFROG AI HLDGS (BFRG)?
